2.08
-0.1(-4.59%)
Currency In NaN
Address
5505 Morehouse Drive
San Diego, CA 92121
United States of America
Phone
858 267 4467
Website
Sector
N/A
Industry
N/A
Employees
89
First IPO Date
N/A
| Name | Title | Pay | Year Born |
| Dr. Peter Flynn Ph.D. | Co-Founder & Strategic Advisor | 499,368 | 1974 |
| Mr. Christopher P. Horan | Chief Technical Operations Officer | 612,234 | 1967 |
| Dr. Subhashis Banerjee M.D. | Chief Medical Officer | 0 | 1957 |
| Mr. Feng Xu | Senior Vice President of Biometrics | 0 | N/A |
| Mr. Benjamin Dewees | Senior Vice President of Regulatory Affairs | 0 | N/A |
| Dr. David Moriarty Ph.D. | Senior Vice President of Clinical Operations | 0 | N/A |
| Dr. Heather Raymon Ph.D. | Senior Vice President of Research & Early Development | 0 | 1965 |
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.